U.S. Renewable Energy Stock News

NYSE:GPOR
NYSE:GPOROil and Gas

Has Gulfport Energy (GPOR) Share Weakness Opened A Long Term Opportunity For Investors

If you are wondering whether Gulfport Energy, at a last close of US$178.80, is attractively priced or if the easy gains are behind it, this article breaks down what the current share price might be implying about the stock's value. The stock has seen a 7.1% decline over the last week, a 13.9% decline over the last month, and a 13.3% decline year to date, set against a 94.6% return over the last 3 years and a 5.0% decline over the last year. Recent coverage has focused on Gulfport Energy's...
NasdaqGS:AUGO
NasdaqGS:AUGOMetals and Mining

Aura Minerals Turnaround Pairs Record Q1 Profits With Higher Dividend

Aura Minerals reported record Q1 profits and record EBITDA, marking a turnaround from a loss in the prior year. The Board declared a dividend that exceeds the company's own minimum payout policy, indicating higher shareholder returns in the period. The stock, NasdaqGS:AUGO, last closed at $81.07, with very large 1 year and 3 year returns and a 62.1% gain year to date. For investors who have been tracking NasdaqGS:AUGO, this update focuses on fresh company news rather than past valuation...
NasdaqGM:RMIX
NasdaqGM:RMIXBasic Materials

Assessing Suncrete (RMIX) Valuation After Its Recent Share Price Momentum

Why Suncrete (RMIX) is on investors’ radar Suncrete (RMIX) has drawn attention after a strong share price move over the past month, with the stock returning 46.5% across that period and 34.6% over the past 3 months. See our latest analysis for Suncrete. That swing in momentum, with a 46.5% 1 month share price return and 35.1% year to date share price return, sits alongside a 39.4% 1 year total shareholder return at a latest close of $15.40. If Suncrete’s recent move has you thinking about...
NasdaqGS:SANA
NasdaqGS:SANABiotechs

Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High

Sana Biotechnology (SANA) is back in focus as CEO Steve Harr prepares to deliver a business overview and company update at the BofA Securities 2026 Healthcare Conference on May 12. See our latest analysis for Sana Biotechnology. At a share price of $3.50, Sana’s 7 day share price return of 6.38% and 30 day share price return of 11.11% contrast with a year to date share price decline of 16.47%. The 1 year total shareholder return of 93.37% sits against weaker 3 and 5 year total shareholder...
NYSE:RJF
NYSE:RJFCapital Markets

Raymond James Bets On AI And ETFs To Deepen Advisor Platform

Raymond James Financial (NYSE:RJF) has rolled out its Client 360 platform and an artificial intelligence learning academy for financial advisors. The company is committing a reported US$1.1b to technology, including AI powered tools aimed at improving advisor productivity and client service. Raymond James has closed its acquisition of Clark Capital Management Group and introduced proprietary active ETFs to expand its asset management menu. For investors following wealth management and...
NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

If AI Healthcare Is The Next Breakout Read These Three Stocks

Artificial intelligence in healthcare sits at the crossroads of powerful data, rising care costs, and a world focused on inflation, energy shocks, and supply chain shifts. While oil, rates, and trade headlines pull markets in different directions, AI tools that can improve accuracy, access, and affordability in medicine are drawing close attention. The Transformative AI Healthcare Stocks screener looks for companies using AI to sharpen diagnostics, personalise treatment, streamline clinical...
NYSE:MANE
NYSE:MANEPharmaceuticals

Is It Too Late To Consider Veradermics (MANE) After A 186% Year To Date Surge?

If you are wondering whether Veradermics’ current share price lines up with its underlying value, this article breaks down what the numbers may indicate about the stock. Veradermics recently closed at US$107.85, with returns of 8.9% over 7 days, 90.2% over 30 days and 185.7% year to date. This puts the current price action firmly in focus for valuation-minded investors. Recent coverage around Veradermics has centered on its position within the Pharmaceuticals industry and how investors are...
NYSE:OHI
NYSE:OHIHealth Care REITs

Omega Healthcare Portfolio Cleanup Aims To Support Dividend Stability

Omega Healthcare Investors (NYSE:OHI) is selling CommuniCare’s skilled nursing assets to lower tenant concentration risk. The move is part of a broader portfolio cleanup that also considers financial pressures at Maplewood and Genesis. The company aims to support dividend stability and overall portfolio health as operator stress continues across the sector. For investors watching NYSE:OHI at a share price of $46.13, this portfolio cleanup follows a very large 3-year return and a 94.0%...
NasdaqGM:MRAM
NasdaqGM:MRAMSemiconductor

Everspin Technologies (MRAM) Is Up 17.7% After $40M Navy MRAM Subcontract And Narrower Q1 Loss - Has The Bull Case Changed?

In April 2026, Everspin Technologies announced a US$40,000,000, 30‑month subcontract with Amentum Services under a U.S. Navy microelectronics RDT&E program, alongside first‑quarter 2026 results showing higher revenue and a smaller net loss than a year earlier. The deal ties Everspin’s Toggle MRAM process technology directly into U.S. defense supply chains, reinforcing its role as an on‑shore memory partner for critical systems. Next, we’ll examine how this US$40,000,000 defense-focused...
NYSE:KMX
NYSE:KMXSpecialty Retail

CarMax Fraud Probe Puts Pricing And Credit Risk Strategy Under Scrutiny

Pomerantz LLP has opened an investigation into CarMax (NYSE:KMX) for potential securities fraud or other unlawful business practices. The inquiry follows CarMax's April 14, 2026 decision to lower used car prices and accept higher credit risk in response to an auto affordability crisis. The combination of a pricing shift and looser credit standards raises questions about risk management, disclosure, and long term business impacts. CarMax runs one of the largest used car retail operations in...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Its Multi‑Year Share Price Slide

If you are wondering whether BioMarin Pharmaceutical's current share price reflects its true value, a useful starting point is understanding how the market has treated the stock recently. BioMarin's share price closed at US$54.12, with returns of 0.4% over 7 days, a 3.7% decline over 30 days, a 9.0% decline year to date, and a 9.5% decline over the last year, alongside longer term 43.3% and 28.3% declines over 3 and 5 years. These returns suggest many investors are likely reassessing whether...
NasdaqGS:CSGS
NasdaqGS:CSGSProfessional Services

Assessing CSG Systems International (CSGS) Valuation After Steady Long Term Shareholder Returns

Why CSG Systems International Is On Investors’ Radar Today CSG Systems International (CSGS) is drawing attention after a period of steady share price performance, leaving investors weighing how its current valuation lines up with recent returns and fundamentals. See our latest analysis for CSG Systems International. At a share price of $80.39, CSG Systems International has seen relatively steady short term share price returns. A 1 year total shareholder return of 25.55% and 5 year total...
NYSE:ANDG
NYSE:ANDGProfessional Services

Assessing Andersen Group (ANDG) Valuation After Strong Recent Share Price Momentum

Event context and recent share performance Andersen Group (ANDG) recently drew investor interest after a session that left the stock at $35.98, with single day and past week returns of 2.27% and 1.70% respectively. Over the past month and past 3 months, Andersen Group has delivered returns of 25.58% and 67.97%, while year to date the stock shows a 47.58% total return. See our latest analysis for Andersen Group. For context, Andersen Group's recent 1 month share price return of 25.58% and 3...
NYSE:PBH
NYSE:PBHPharmaceuticals

Has Prestige Consumer Healthcare (PBH) Fallen Too Far After Its 37% One-Year Share Price Drop?

If you are wondering whether Prestige Consumer Healthcare is attractively priced or just a value trap, the stock's recent performance and fundamentals give you plenty to weigh up. The share price recently closed at US$54.59, with returns of a 3.1% decline over 7 days, a 1.9% decline over 30 days, a 10.8% decline year to date, and a 37.3% decline over the last year, while the 3 year and 5 year returns stand at a 6.4% decline and 12.3% respectively. Recent coverage has focused on Prestige...
NasdaqGS:PFG
NasdaqGS:PFGInsurance

Is It Time To Reassess Principal Financial Group (PFG) After Strong Multi Year Share Price Gains

Investors may be asking whether Principal Financial Group at around US$100 per share is offering fair value or a potential mispricing opportunity right now. The stock has recently seen a 0.9% decline over 7 days, compared with stronger returns of 9.9% over 30 days, 11.9% year to date, 31.8% over 1 year, 62.3% over 3 years and 83.4% over 5 years. Recent coverage has focused on how investors are reassessing insurers like Principal Financial Group in light of broader sector trends and shifting...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

CG Oncology (CGON) Deep LTM Losses Test Bullish Late Stage Pipeline Narratives

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...
NYSE:NVST
NYSE:NVSTMedical Equipment

Is It Time To Reassess Envista Holdings (NVST) After Its Recent Share Price Pullback

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...
NYSE:UI
NYSE:UICommunications

Ubiquiti (UI) Earnings Surge And 29.9% Margin Spark Debate On Valuation Premium

Ubiquiti (UI) has put up another big quarter, with Q2 2026 revenue of US$814.9 million and basic EPS of US$3.86, while trailing 12 month EPS sits at US$14.69 on revenue of about US$3.0 billion and earnings growth over that period is described as a 99.7% jump. The company has seen quarterly revenue move from US$599.9 million and EPS of US$2.26 in Q2 2025 to US$814.9 million and EPS of US$3.86 in Q2 2026, and trailing 12 month net profit margin is now stated at 29.9% versus 20.7% a year...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

CoreWeave (CRWV) Q4 Loss Of US$452m Reinforces Profitability Concerns Despite Revenue Scale

CoreWeave (CRWV) has just wrapped up FY 2025 with Q4 total revenue of US$1.6b, a basic EPS loss of US$0.89 and net income loss of US$452.0m. This caps off a year in which trailing twelve month revenue reached US$5.1b alongside a TTM basic EPS loss of US$2.75. Over the past six reported quarters, the company has seen revenue move from US$584.0m in Q3 2024 to US$1.6b in Q4 2025. During the same period, quarterly basic EPS has ranged between a loss of US$0.22 and a loss of US$1.82, so the latest...
NYSE:MUR
NYSE:MUROil and Gas

Is Murphy Oil (MUR) Still Attractive After An 88% One Year Share Price Surge

If you are wondering whether Murphy Oil at around US$38.27 is offering value or just riding momentum, the recent share performance gives you plenty to think about. The stock has seen a 1 year return of 88.2% and is up 17.8% year to date, despite shorter term pullbacks with a 7 day return showing an 8.4% decline and a 30 day return showing a 10.5% decline. Recent coverage has focused on Murphy Oil as part of broader conversations around US oil and gas stocks, with attention on how producers...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN) Is Down 16.8% After Convertible Notes Deal Extends Cash Runway - What's Changed

In early May 2026, Ocugen reported first-quarter revenue of US$1.53 million alongside a net loss of US$19.18 million, while also closing a US$115 million private offering of 6.75% Convertible Senior Notes due 2034 and using about US$32.7 million to retire its Avenue loan. These updates both highlight Ocugen’s ongoing cash burn and materially improve its liquidity profile, with management indicating the new financing extends the company’s cash runway and supports continued advancement of its...
NasdaqGS:SLDE
NasdaqGS:SLDEInsurance

Slide Insurance Enters California As Valuation Gap And Growth Risks Stand Out

Slide Insurance Holdings (NasdaqGS:SLDE) has entered the California market with a new excess and surplus lines residential property insurance program. The company has written its first California policy, marking the start of its operations in one of the largest U.S. property insurance markets. For investors watching property insurers, California represents a complex and heavily scrutinized market, especially for residential coverage. By using an excess and surplus lines structure, Slide...
NasdaqGS:UPWK
NasdaqGS:UPWKProfessional Services

Upwork (UPWK) Margin Compression To 14.7% Tests Bullish Undervaluation Narrative

Upwork (UPWK) has just wrapped FY 2025 with fourth quarter revenue of US$198.4 million and basic EPS of US$0.12, alongside net income of US$15.6 million. This rounds out a year where trailing twelve month revenue came in at US$787.8 million and EPS at US$0.87. Over recent quarters the company has seen revenue move from US$191.5 million in Q4 2024 to between US$192.7 million and US$201.7 million across FY 2025, while quarterly EPS has ranged from US$0.12 to US$0.28. This sets up a story that...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona (XRAY) Now Offering Value After A 28% One Year Share Price Slide

If you are wondering whether DENTSPLY SIRONA stock is starting to look interesting at current levels, its recent price and valuation signals give you a lot to think about. The share price sits at US$10.96 after a 6.7% decline over the last week, a 4.9% decline over the last month and a 28.5% decline over the last year, which may change how you view both its risk and potential reward. Recent coverage around DENTSPLY SIRONA has focused on its position within the medical equipment space and how...